Clovis Oncology Net Income

Clovis Oncology posts a net income of $-250M as of September 2022. That compares with $-300M in the prior-year period — up 15.8% year over year. That is below the Healthcare sector average of $16B. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, Clovis Oncology's net income was $-300M. The latest reading is $-250M — a 15.8% year-over-year increase (period ending September 2022). Use the history and growth charts on this page for a longer lookback.

For Healthcare stocks, a net income near $16B is typical. Clovis Oncology's $-250M is lower that level. That is roughly 101.6% below the sector mean. Whether that is a warning or an opportunity depends on growth outlook and other fundamentals shown elsewhere on Stockcircle.

Net Income is one piece of Clovis Oncology's financial statement story. At $-250M, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for CLVS's net income usually means three checks: (1) trend versus prior periods, (2) level versus peers (average $16B), and (3) consistency with growth and profitability. This page covers the first two; Clovis Oncology's other metric pages and overview cover the third.